DBV Technologies Plans Strategy For Peanut Allergy Debut In U.S.
This article was originally published in The Pink Sheet Daily
Executive Summary
The French biotech will set out its stall first in the U.S., where peanut allergy is a major concern, and plans to tackle the life-threatening condition with its transdermal patch without relying on local partners.
You may also be interested in...
Aimmune Gets $145m From Nestlé To Advance Food Allergy Immunotherapies
With the sizeable investment, Nestlé Health Sciences also gets a three-month right of first negotiation for licensing or partnering to develop any Aimmune candidates, including Phase III AR101 for peanut allergy.
Peanut Allergy Targeted By DBV Technologies As It Raises $55 Million In Second Euro Biotech IPO This Year
France's DBV Technologies lists on NYSE Euronext in Paris and targets peanut and other food allergies for the first clinical studies of its epicutaneous patches as allergy desensitization therapies.
Pipeline Watch: Phase III Readouts in Wilson Disease, Parkinson's Disease And COVID-19
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.